http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2745260-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_764a0ebcface568d4a5b66163ac82423 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e733c83bd433c838849ca0cebe20eddf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_215108ba4a82f1e47aeda96abb2deb7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2ea4d0cb6912f7eefc94e8798427fe4 |
| publicationDate | 2021-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2745260-C1 |
| titleOfInvention | Method for prediction of hemorrhagic manifestations in crimean hemorrhagic fever |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to medicine and namely to infectious diseases. To predict hemorrhagic manifestations in Crimean hemorrhagic fever in a patient with the moderate course of Crimean hemorrhagic fever, the level of thrombocritis, the degree of platelet aggregation, the concentration of fibrinogen in the blood plasma, activated partial thromboplastin time, activated thromboplastin time, activated thromboplastin time, activated thromboplastin time, activated thrombocytoplasmic thrombocyte time, activated thrombocyte recalcification time, thrombocyte and the thrombocyte level ratio of platelet malondialdehyde level to platelet catalase activity are identified. Hemorrhagic complications are predicted in a patient with a decrease in the thrombocyte level to 0.05% and below, a decrease in the degree of platelet aggregation to 4.4% and below, a decrease in the concentration of fibrinogen in blood plasma to 2.5 g/l and below, an increase in the activated partial thromboplastin time up to 45.2 s or more, an increase in the activated time of plasma recalcification to 98.2 s or more, an increase in the level of platelet malondialdehyde to 40 mcmol/l and above, a decrease in the activity of platelet catalase to 223 mkat/ml and below and an increase in the ratio of the level platelet malondialdehyde to platelet catalase activity up to 0.18 and higher.EFFECT: method allows to simplify prediction of hemorrhagic manifestations in patients with the moderate course of Crimean hemorrhagic fever and to ensure this prediction has an informative value.1 cl, 3 ex |
| priorityDate | 2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 311.